Pharmacy Management Drug Policy

Size: px
Start display at page:

Download "Pharmacy Management Drug Policy"

Transcription

1 SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines take into account physician society recommendations, the views of the physicians practicing in relevant clinical areas, the needs of the members in consultation with their providers, and other relevant factors to the extent practicable. Clinical criteria is reviewed and approved for use on an annual basis. Criteria are accessible to network providers, members, and prospective members upon request. Criteria may be verbally requested by calling 1 (800) , or submitting a fax request to 1 (888) Requests may also be submitted in writing to P.O. Box 240, Pittsford, N.Y Providers may also submit feedback regarding criteria by visiting DESCRIPTION: Pulmonary arterial hypertension (PAH) is characterized by sustained elevation of pulmonary artery pressure. The condition is uncommon but is associated with a high mortality rate. Some causes of pulmonary hypertension include congenital heart defects, connective tissue disease, HIV infection, blood clots, liver disease, and medication (ex. Fenphen). The disease can also have an unknown cause (primary pulmonary hypertension, PPH). The most common symptoms caused by PAH are unusual fatigue, SOB, chest pain, fainting, and peripheral edema. Careful invasive assessment of pulmonary hemodynamics is critical in the evaluation of any patient with suspected PAH. All patients that are suspected of having PAH after non-invasive evaluation (chest X-ray or echocardiogram) should undergo right heart catheterization (RHC) prior to initiating therapy. RHC can be performed safely even in patients with severe pulmonary hypertension and right heart failure. Treatment goals include improvement in patient symptoms such as dyspnea and exercise endurance, lowering pulmonary artery pressure, prevent progression of disease and improve survival. Medical management for PAH includes oral calcium-channel blockers, anticoagulants, oxygen therapy, endothelial-receptor antagonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and prostacyclins (iloprost, treprostinil, epoprostonol) and the newer class of sgc inhibitors (riociguat). Lung and heart transplants have been performed in those patients that are refractory to medical management. Class 1 Class 2 Class 3 Class 4 New York Heart Association Functional Classification Ordinary physical activity does not cause symptoms Comfortable at rest, ordinary physical activity causes symptoms Comfortable at rest, less than ordinary activity (ADLs) causes symptoms Symptoms at rest This policy is applicable to the following drugs that are FDA approved for the treatment of PAH Adcirca Adempas Flolan (epoprostenol) 1

2 Letairis Orenitram Opsumit Remodulin Revatio (sildenafil) Tracleer Veletri Ventavis PAH Policy Criteria: 1. The patient must have a diagnosis of Pulmonary Arterial Hypertension which has been confirmed by a right heart catheterization. 2. The right heart catheterization must demonstrate the following: Mean pulmonary artery pressure (PAP) of to 25 mmhg at rest AND Pulmonary capillary wedge pressure to 15 mm Hg at rest 3. Patient must be followed by and drug therapy prescribed by a cardiologist or pulmonologist. 4. Adcirca and generic sildenafil will be approved as initial treatment for anyone with a confirmed diagnosis of PAH. 5. New starts for Letairis, Tracleer, Revatio or Opsumit will require a trial of generic sildenafil or Adcirca prior to approval of one of these agents. 6. New starts for Adempas for a diagnosis of PAH will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval. Past treatment with a prostacyclin (Flolan, Veletri, Tyvaso, Remodulin or Ventavis) will also be taken in to consideration if used as one of two previous therapies. 7. New starts for Orenitram will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval. Past treatment with a prostacyclin (Flolan, Veletri, Tyvaso, Remodulin or Ventavis) will also be taken in to consideration if used as one of two previous therapies. 8. New starts for Flolan (epoprostenol), Remodulin, Tyvaso, Veltri, and Ventavis will require a trial of sildenafil or Adcirca and an endothelin receptor antagonist (Letairis, Tracleer or Opsumit) prior to approval for lower risk individuals (typically WHO Class II and III). a. Patients at high risk (WHO Class IV) may require continuous treatment with IV prostacyclin as initial therapy. 9. Combination therapy has been studied for the treatment of PAH. The goal of combination therapy should be to maximize efficacy, while minimizing toxicity. For individuals who have inadequate response, combination therapy (with drugs with different mechanisms of action) can be considered. Combination therapy should only be attempted by those with the expertise to monitor such high risk individuals. Adempas specific criteria: 1. Can be used for the treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) and have: a. Recurrent or persistent disease after surgical disease OR b. Inoperable disease determined by V/Q scan and/or pulmonary angiography 2

3 3 Exclusion Criteria: 1. Conditions considered investigational will not be covered. Conditions considered investigational due to lack of peer-reviewed literature for which efficacy or safety data is not yet available include, but are not limited to: Ischemic vascular diseases Congestive heart failure Chronic obstructive pulmonary disease 2. The use of Revatio or Adcirca and nitrates concurrently is contraindicated and therefore will not be covered. 3. Revatio (Sildenafil 20mg) and Adcirca will not be authorized for a diagnosis of erectile dysfunction as there are FDA approved medications for this diagnosis. POLICY GUIDELINES: 1. Prior authorization is contract dependent. 2. Patient must have a right heart catheterization to diagnose Pulmonary Arterial Hypertension 3. Patient must be followed by a cardiologist or pulmonologist 4. Adcirca, Adempas, Revatio (sildenafil), Opsumit, Orenitram, and Tracleer are covered under the pharmacy benefit. 5. Ventavis is covered under the medical benefit to coordinate care with the necessary supplies. Proper verification (based on Part B vs D determination) is necessary for Medicare requests. 6. Tyvaso is self-administered and therefore should be processed under the pharmacy benefit. Proper verification (based on Part B vs D determination) is necessary for Medicare requests. 7. Remodulin, Flolan (epoprostenol) and Veletri are covered under the medical benefit. 8. Sildenafil (Revatio) has been shown to be safe and effective up to a maximum dose of 80mg three times a day for the treatment of PAH. Doses above FDA approval will require documentation of a trial of the lower FDA approved dose which was shown to be ineffective. 9. Tadalafil (Adcirca) has been shown to be safe and effective up to a maximum dose of 40mg once a day. Doses above FDA approval will require documentation of a trial of the lower FDA approved dose which was shown to be ineffective. 10. Maximum dosing of bosentan (Tracleer) is 125mg twice a day. 11. Maximum dosing of ambrisentan (Letairis) is 10mg once a day. 12. Maximum dosing of riociguat (Adempas) is 2.5mg three times a day. 13. Maximum dosing of macitentan (Opsumit) is 10mg once a day. 14. There is no FDA approved maximum dose of oral treprostinil Orenitram, but the maximum dose allowed within the clinical trials was 16mg twice a day. 15. Surgery is the only definitive therapy for chronic thromboembolic pulmonary hypertension (CTEPH), with pulmonary thromboendarterectomy being the surgical procedure of choice

4 4 Please see YourCare PA list for related codes. REFERENCES: 1. Badesch D, et al. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Clinical Practice Guidelines. CHEST 2004; 126:35S-57S. 2. Sitbon O, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a doseresponse study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: Sitbon O, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: Opitz CF, et al. Assessment of the vasodilator response in primary pulmonary hypertension: comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003; 24: Barst RJ, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Eng J Med 1996; 334: Rich S, et al. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: Shapiro SM, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: McLaughlin VV, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 2003; 40: Simonneau G, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: Hoeper MM, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Eng J Med 2000; 342: Channick RN, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: Michelakis E, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105: Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J Dec;28(6): Voswinckel R, Enke B, Reichenberger F, et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol. 2006;48(8): Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest Sep;132(3): Channick RN, Olschewski H, Seeger W, et al. Safety and efficacy of inhaled treprostinil as add- on therapy to bosentan in pulmonary arterial hypertension. J Am Coll Cardiol. 2006;48(7):

5 17. Flolan package insert, GSK. September Tracleer package insert, Actelion Inc. March Remodulin package insert, Baxter. November Ventavis package insert, CoTherix Inc. December Revatio package insert, Pfizer, June Letairis package insert, Gilead Sciences, Inc. June Adcirca package insert, Eli Lilly & Company marketed by United Therapeutics May McLaughlin VV et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. J of American College of Cardiology. 53(17) Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2009:30:

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered

More information

PULMONARY ARTERIAL HYPERTENSION AGENTS

PULMONARY ARTERIAL HYPERTENSION AGENTS Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar

More information

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)

1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca) This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic

More information

ADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION

ADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members

More information

Clinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88

Clinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88 Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis

More information

Drug Class Monograph. Policy/Criteria:

Drug Class Monograph. Policy/Criteria: Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),

More information

TREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650

TREPROSTINIL Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 Generic Brand HICL GCN Exception/Other TREPROSTINIL REMODULIN 23650 SODIUM TREPROSTINIL TYVASO 36537 36539 36541 TREPROSTINIL ORENITRAM 40827 **Please use the criteria for the specific drug requested**

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Adcirca) Reference Number: HIM.PA.SP23 Effective Date: 05/17 Last Review Date: Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at

More information

Pulmonary Hypertension Drugs

Pulmonary Hypertension Drugs Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 05/22/2015 Section: Prescription Drugs

More information

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications

Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Pharmacy Medical Necessity Guidelines: Pulmonary Hypertension Medications Effective: January 15, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

More information

Clinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16

Clinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important

More information

Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review

Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important

More information

Pulmonary Hypertension Drugs

Pulmonary Hypertension Drugs Pulmonary Hypertension Drugs Policy Number: Original Effective Date: MM.04.028 10/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 05/25/2012 Section: Prescription Drugs Place(s) of Service:

More information

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvasco) Reference Number: CP.PHAR.199

Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvasco) Reference Number: CP.PHAR.199 Clinical Policy: (Orenitram, Remodulin, Tyvasco) Reference Number: CP.PHAR.199 Effective Date: 03/16 Last Review Date: 03/17 See Important Reminder at the end of this policy for important regulatory and

More information

Pulmonary Arterial Hypertension Drug Prior Authorization Protocol

Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Pulmonary Arterial Hypertension Drug Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190 Effective Date: 07.01.18 Last Review Date: 01.12.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Revision Log See Important Reminder at the

More information

Patient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community

Patient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community Treatment of Pulmonary Hypertension in a Community Hospital Serena Von Ruden, PharmD, RN, BSN St. Francis Hospital Federal Way, WA Franciscan Health System HPI: 66 year old male with advanced oxygendependent

More information

Oral Therapies for Pulmonary Arterial Hypertension

Oral Therapies for Pulmonary Arterial Hypertension Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Revatio) Reference Number: CP.PHAR.197 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Adcirca) Reference Number: CP.PHAR.198 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Revatio) Reference Number: CP.PHAR.197 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM*, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Opsumit) Reference Number: CP.PHAR.194 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request

More information

Clinical Policy: Bosentan (Tracleer) Reference Number: CP.PHAR.191

Clinical Policy: Bosentan (Tracleer) Reference Number: CP.PHAR.191 Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190

Clinical Policy: Ambrisentan (Letairis) Reference Number: CP.PHAR.190 Clinical Policy: (Letairis) Reference Number: CP.PHAR.190 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM*, Medicaid Description (Orenitram, Remodulin,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, HIM*, Medicaid Coding Implications Revision Log

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Coding Implications

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Tracleer) Reference Number: CP.PHAR.191 Effective Date: 03.16 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Flolan, Veletri) Reference Number: CP.PHAR.192 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: CP.PHAR.199 Effective Date: 07.01.18 Last Review Date: 01.12.18 Line of Business: Oregon Health Plan Coding Implications Revision

More information

Clinical Policy: Tadalafil (Adcirca) Reference Number: CP.PHAR.198

Clinical Policy: Tadalafil (Adcirca) Reference Number: CP.PHAR.198 Clinical Policy: (Adcirca) Reference Number: CP.PHAR.198 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ventavis) Reference Number: CP.PHAR.193 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Coding Implications Revision

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi

More information

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007

National Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007 Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced

Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University

More information

Therapeutic Categories Outlook

Therapeutic Categories Outlook Equity Research Health Care Therapeutic Categories Outlook Comprehensive Study February 2017 Alzheimer s Disease Bone Diseases Cardiovascular Central Nervous System Dermatology Diabetes/Obesity Epilepsy

More information

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University

Pulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of

More information

Pulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes

Pulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal

More information

Advances in Pharmacotherapy of PAH

Advances in Pharmacotherapy of PAH 24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose

More information

Referral Forms for TYVASO and REMODULIN

Referral Forms for TYVASO and REMODULIN Referral Forms for TYVASO and REMODULIN HOW TO GET STARTED Tyvaso and Remodulin are available only through select Specialty Pharmacy Services (SPS) providers. Follow these 5 simple steps to complete each

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.23 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: September 15, 2017 Sildenafil

More information

Teaching Round Claudio Sartori

Teaching Round Claudio Sartori Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2

More information

Updates on Pulmonary Hypertension Treatment

Updates on Pulmonary Hypertension Treatment Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness

More information

Approach to Pulmonary Hypertension in the Hospital

Approach to Pulmonary Hypertension in the Hospital Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences

More information

2012 CADTH Symposium. April 2012

2012 CADTH Symposium. April 2012 2012 CADTH Symposium Using Mixed Treatment Comparisons to compare Oral Treatments for Pulmonary Arterial Hypertension and Inform Policy Decisions by a Public Drug Plan April 2012 Objective of this Presentation

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)

More information

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines

THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest

More information

Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension

Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Advanced Therapies for Pharmacological Treatment of Pulmonary Hypertension Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description

More information

Pulmonary Hypertension: Another Use for Viagra

Pulmonary Hypertension: Another Use for Viagra Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A

More information

Bosentan for treatment of pulmonary arterial hypertension (I)

Bosentan for treatment of pulmonary arterial hypertension (I) KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,

More information

Pulmonary Arterial Hypertension (PAH) Treatments

Pulmonary Arterial Hypertension (PAH) Treatments Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health

More information

Treatment of Paediatric Pulmonary Hypertension

Treatment of Paediatric Pulmonary Hypertension Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships

More information

Sildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016

Sildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate

More information

4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology

4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary

More information

22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment

22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment 22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School

More information

National Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008

National Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008 Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.

More information

Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension

Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension Policy Number: 5.01.09 Last Review: 01/2018 Origination: 6/2013 Next Review: 02/2019 Policy Blue Cross and Blue Shield

More information

PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER

PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Pulmonary Hypertension, Drug Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: pulmonary_hypertension_drug_management 06/1998 3/2018 3/2019 3/2018

More information

Real-world experience with riociguat in CTEPH

Real-world experience with riociguat in CTEPH Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International

More information

Pulmonary Hypertension in 2012

Pulmonary Hypertension in 2012 Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Opsumit) Reference Number: CP.CPA.107 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH)

Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Injectable Agents for the Treatment of Pulmonary Arterial Hypertension (PAH) Clinical Edit Information Included in this Document

More information

Disclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline

Disclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin

More information

Update on the Management of Pulmonary Hypertension

Update on the Management of Pulmonary Hypertension Update on the Management of Pulmonary Hypertension Weston Bush, PharmD, BCPS Clinical Pharmacy Specialist, SICU University Hospitals Case Medical Center Disclosures None Treatment (Conventional/Supportive)

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. SILDENAFIL oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline

More information

Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine

Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of

More information

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)

INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE

More information

ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO

ACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Tadalafil (Adcirca), Sildenafil citrate (Revatio) Reference Number: CP.CPA.72 Effective Date: 11.16.16 Last Review Date: 08.17 Line of Business: Medicaid Medi-Cal Revision Log See Important

More information

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)

The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)

More information

Update in Pulmonary Arterial Hypertension

Update in Pulmonary Arterial Hypertension Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with

More information

Pulmonary Hypertension A-Z

Pulmonary Hypertension A-Z Pulmonary Hypertension A-Z Lana Melendres-Groves UNM Pulmonary Hypertension Program Director Assistant Professor of Medicine Pulmonary/Critical Care Division 9/17/16 Disclosures Advisory board member Actelion

More information

Where are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA

Where are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress

More information

INPATIENT USE OF PARENTERAL PROSTACYCLINS IN AN ACADEMIC MEDICAL CENTER

INPATIENT USE OF PARENTERAL PROSTACYCLINS IN AN ACADEMIC MEDICAL CENTER INPATIENT USE OF PARENTERAL PROSTACYCLINS IN AN ACADEMIC MEDICAL CENTER Maria Guido, PharmD, BCPS Clinical Pharmacy Specialist Internal Medicine University of Cincinnati Medical Center OSHP 77 th Annual

More information

Phosphodiesterase Type 5 Inhibitors: ADCIRCA (tadalafil) oral tablet REVATIO (sildenafil) oral suspension and tablet

Phosphodiesterase Type 5 Inhibitors: ADCIRCA (tadalafil) oral tablet REVATIO (sildenafil) oral suspension and tablet REVATIO (sildenafil) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This

More information

4/18/2018 DISCLOSURE (AND DISCLAIMER)

4/18/2018 DISCLOSURE (AND DISCLAIMER) DISCLOSURE (AND DISCLAIMER) PEDIATRIC PULMONARY HYPERTENSION PHARMACOTHERAPY 11th International Conference Neonatal & Childhood Pulmonary Vascular Disease April 19, 2018 I have no conflicts of interests

More information

2016 PHARMACOLOGY UPDATE: PULMONARY ARTERIAL HYPERTENSION

2016 PHARMACOLOGY UPDATE: PULMONARY ARTERIAL HYPERTENSION 2016 PHARMACOLOGY UPDATE: PULMONARY ARTERIAL HYPERTENSION Maureen A Seckel APRN, ACNS-BC, CCNS, CCRN, FCCM CNS Medical Pulmonary Critical Care Sepsis Leader CCHS PAH Team Member WHAT IS PAH? Pulmonary

More information